Mesa Laboratories Inc. director R. Tony Tripeny reported an open-market purchase of 900 shares of the company’s common stock on 2026-08-13 at a price of $113.69 per share. Following this transaction, Tripeny’s directly held stake increased to 6,298 shares of common stock.
Mesa Laboratories, Inc. reported Q1 FY2027 revenue of $60,138, up 1.0% from $59,543 a year earlier. Gross profit rose to $39,012, with gross margin improving to 64.9% from 62.0% as lower third‑party labor, supply‑chain efficiencies and favorable mix aided margins, especially in Biopharmaceutical Development and Clinical Genomics.
Operating expense fell 5.6% to $31,981, lifting operating income to $7,031 from $3,064. Net income was $2,830 versus $4,742, largely reflecting a prior‑year foreign‑currency gain that did not recur. Operating cash flow strengthened to $14,736, supporting an $8.7 million net debt reduction; cash ended at $30,695 with $77,250 outstanding on the Revolver and full covenant compliance.
Sterilization and Disinfection Control revenue declined 3.6% on shipment‑timing issues, while Biopharmaceutical Development and Calibration Solutions grew 5.0% and 7.6%, respectively; Clinical Genomics was flat with continued China softness. Mesa paid a $0.16 per‑share dividend and expects a potential partial release of its U.S. deferred tax valuation allowance within 12 months, which could lower its 35.0% effective tax rate. No material legal proceedings or control weaknesses were identified.
Mesa Laboratories, Inc. reported first fiscal quarter 2027 results for the three months ended June 30, 2026. Revenues were $60,138 thousand, up 1.0% year over year, with growth in Biopharmaceutical Development and Calibration Solutions partly offset by declines in Sterilization and Disinfection Control and essentially flat Clinical Genomics.
Operating income rose 129% to $7,031 thousand as gross profit improved and operating expenses declined. However, net income was $2,830 thousand, down 40.3%, or $0.49 per diluted share, mainly due to nonoperating expense of $2,678 thousand versus nonoperating income of $3,948 thousand in the prior year, which had included approximately $6,150 thousand of unrealized foreign currency gains.
Non-GAAP Adjusted Operating Income (AOI) increased 16.5% to $15,035 thousand, or $2.61 per diluted share, and AOI excluding unusual items (a $382 thousand legal settlement) was $15,417 thousand, up 19.5%. The company repaid $8,656 thousand of debt, bringing its Total Net Leverage Ratio to 1.85, below its stated target of 2.0. Management emphasized disciplined execution, capital allocation and plans to provide full-year guidance in November.
Mesa Laboratories, Inc. reported that its Board of Directors approved an amended and restated Code of Ethics and Business Conduct on July 30, 2026, effective immediately. The updated Code replaces the prior version.
The amendments are described as updating and modernizing the Code, including specific revisions related to external communications and social media, along with other clarifying, administrative, compliance and procedural updates. The complete Code of Ethics and Business Conduct is provided as Exhibit 14.1 to the report.
Mesa Laboratories, Inc. asks shareholders to vote at its 2026 annual meeting on three items: electing seven directors, ratifying Baker Tilly US, LLP as independent auditor for fiscal 2027, and approving a non-binding advisory resolution on named executive officer compensation; the Board recommends voting FOR all proposals.
The company describes itself as a global designer and manufacturer of life sciences tools and quality-control solutions, operating under “The Mesa Way” continuous-improvement system. For fiscal 2026 it reports total revenues of $249.1 million, operating income of $18.5 million, and non-GAAP adjusted operating income of $63.5 million representing 25.5% of revenues, with its total net leverage ratio reduced from approximately 3.0 to approximately 2.1.
The proxy details a governance framework with a majority-independent, annually elected seven-member Board, a Lead Independent Director, stock ownership guidelines, and a clawback policy. Executive pay is heavily performance-based, emphasizing annual incentives and PSU/RSU equity awards tied to relative total shareholder return, with prior say-on-pay support of 94.2% of votes cast.
Mesa Laboratories, Inc. amendment to a Schedule 13G/A reports that Long Path-affiliated entities collectively beneficially hold 477,126 shares of Common Stock, equal to 8.6% of the class. Percentage ownership is calculated from 5,524,931 shares outstanding as of May 21, 2026.
The filing names Long Path Smaller Companies Fund, Long Path Fund GP, Long Path Partners, Long Path Holdings LLC, William Thomas Brennan and Brian Paul Nelson as reporting persons and states the shares are directly held by the Fund with disclaimers of beneficial ownership by each reporting person except for pecuniary interest.
Mesa Laboratories CAO Lyndsey Elizabeth Crennen reported a mix of equity compensation events and a small tax-related share sale. On June 18, 2026, she exercised restricted stock units and performance share units for a total of 726 shares of common stock and received a 263-share grant, all as direct holdings. A subsequent sale of 442 shares of common stock on June 22, 2026 at $89.502 per share was executed to cover taxes related to the June 18, 2026 vesting of RSUs and PSUs and occurred under a 10b-1 plan, according to the footnotes. Following these transactions, she directly holds 2,020 shares of Mesa Laboratories common stock.
Mesa Laboratories senior vice president of operations Brian David Archbold reported a mix of stock compensation activity and a modest sale of common shares. On June 18, 2026, he received a grant or award of 1,859 shares of common stock and exercised restricted stock units (RSUs) covering a total of 3,324 shares, converting them into common stock at a stated price of $95.10 per share for reporting purposes. Related RSU entries show derivative positions being fully converted into common stock.
On June 22, 2026, Archbold executed an open-market sale of 2,516 shares of Mesa Laboratories common stock at an average price of about $89.50 per share. After these transactions, he directly holds 6,377 common shares, indicating that a portion of the newly acquired stock was retained while some was sold for liquidity.
Mesa Laboratories CFO John Sakys reported multiple equity transactions in Mesa Laboratories common stock. On June 18, 2026, he received a grant of 2,282 shares of common stock and exercised restricted stock units (RSUs) that converted into 2,756 and 1,036 shares of common stock.
On June 22, 2026, he sold 2,827 shares at an average price of $89.502 per share. A footnote states these shares were sold to cover taxes related to the vesting of RSUs and performance share units on June 18, 2026, and that the transaction was executed under a Rule 10b5-1 trading plan.
After these transactions, Sakys held 19,785 Mesa Laboratories shares directly, plus 50 shares indirectly as custodian for his children.
MLAB submitted a Rule 144 notice reporting proposed resale of 2,827 shares of Common Stock tied to restricted stock vesting. The filing lists a broker-dealer Fidelity Brokerage Services LLC and an aggregate dollar figure of $253,021.88 on the cover. The excerpt also shows 1,223 shares sold on 06/16/2026 for $123,849.54 as transactions in the prior three months.